Department of Dermatology, Mount Sinai School of Medicine, New York, New York; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York.
Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York.
J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.
Accurate assessment of prognosis remains clinically challenging in stage II to III cutaneous melanoma. Studies have implicated CD2 in immune surveillance, T-cell activation, and antitumor immunity, but its role in melanoma progression warrants further investigation.
We sought to investigate the prognostic role of CD2 in primary cutaneous melanoma.
Patients with American Joint Committee on Cancer stage II and III cutaneous melanoma were identified by retrospective review of dermatopathology databases from 2001 to 2010 at Mount Sinai Medical Center and Geisinger Medical Center. Additional patients were provided by New York University Medical Center based on retrospective review and tissue availability. Immunohistochemistry was performed on tumors from 90 patients with known recurrence status and documented follow-up.
Primary tumors from patients who developed recurrent disease had fewer CD2(+) cells (P = .0003). In multivariable analyses including standard clinicopathologic predictors, CD2 was an independent predictor of disease recurrence (P = .008) and overall survival (P = .007). CD2 count correlated with characterization of tumor-infiltrating lymphocytes (P = .0004). Among the intermediate prognosis group of patients with nonbrisk tumor-infiltrating lymphocytes, CD2 count was predictive of disease recurrence (P = .0006) and overall survival (P = .0318).
Our retrospective design may have resulted in incomplete representation of patients lacking documented follow-up.
CD2 may be an independent predictor of disease recurrence and overall survival among patients with primary cutaneous melanoma.
在 II 期至 III 期皮肤黑色素瘤中，准确评估预后仍然具有临床挑战性。研究表明 CD2 参与免疫监视、T 细胞激活和抗肿瘤免疫，但它在黑色素瘤进展中的作用需要进一步研究。
我们旨在研究 CD2 在原发性皮肤黑色素瘤中的预后作用。
通过回顾性审查 2001 年至 2010 年在西奈山医疗中心和盖辛格医疗中心的皮肤科病理学数据库，确定了美国癌症联合委员会（AJCC）分期 II 和 III 期皮肤黑色素瘤患者。根据回顾性审查和组织可用性，纽约大学医学中心提供了更多患者。对 90 名已知复发状态和记录随访的患者的肿瘤进行免疫组织化学染色。
发生复发疾病的患者的原发肿瘤中 CD2(+)细胞较少（P =.0003）。在包括标准临床病理预测因子的多变量分析中，CD2 是疾病复发（P =.008）和总生存（P =.007）的独立预测因子。CD2 计数与肿瘤浸润淋巴细胞的特征相关（P =.0004）。在非活跃肿瘤浸润淋巴细胞的中等预后组患者中，CD2 计数可预测疾病复发（P =.0006）和总生存（P =.0318）。
我们的回顾性设计可能导致缺乏记录随访的患者代表性不完整。
CD2 可能是原发性皮肤黑色素瘤患者疾病复发和总生存的独立预测因子。
